Jesús Martin-Garcia, Chief Executive Officer
Jesús began his career in 1983 at the World Economic Foundation, and in 1989 at McKinsey & Co where he led studies in the pharmaceutical and food industries.
By 1993, he chose the entrepreneurial path by creating, investing and leading start-ups in Switzerland and the United States. He was for example a co-founder of LeShop in 1996, which became the Swiss leader in e-commerce and was sold to Migros.
In 2003, he created Eclosion, a public-private partnership for translating scientific discoveries in the field of life sciences into innovative drugs with disruptive potential. This unique structure was instrumental in the creation of GeNeuro, which was led by Jesús since its creation in 2006.
Jesús holds a bachelor's degree in industrial sciences, a master in law from Geneva University and an MBA from Harvard Business School. He serves on the board of several biotech companies and industrial and business associations.


Dr. François Curtin, MD, MPhil, MBA, Chief Operating Officer
François graduated with an MD from Geneva Medical School and obtained a master in medical statistics from the London School of Hygiene and Tropical Medicine. He also has an MBA from Warwick Business School.  After several years in academia, he joined Swissmedic, the Swiss medicines agency where he was responsible for the registration and market surveillance of neuropsychiatric drugs. He then joined Serono SA, now Merck Serono, where he worked in clinical and business development. François was the CEO of GeNeuro from 2009 to 2015.


Dr. Hervé Perron, HDR, Chief Scientific Officer
Hervé has a PhD in Virology and wrote a doctoral dissertation on neuroimmunology. He is the author of over 120 peer-reviewed publications and patents and is a referee for various scientific journals. He was Research Director of R&D within bioMérieux for the development of in vitro diagnostics for neurological diseases. Hervé was Scientific Director of bioMérieux STELHYS, a spin-off dedicated to the evaluation of developments in upstream research projects. Hervé is a co-founder and Chief Scientific Officer of GeNeuro and the general manager of GeNeuro-Innovation.


Prof. Dr. Alois B. Lang, Chief Development Officer
Alois has a PhD degree from the Swiss Federal Institute of Technology of Zurich and he did his postdoctoral training at the University Hospital of Zurich and with the Department of Immunology of Cetus Inc., Palo Alto, USA. He is Professor of Immunology at the Faculty of Medicine of the University of Berne. Alois was Head of Research Immunology and Project Manager at Berna Biotech, Berne, and a co-founder and Chief Scientific Officer of the antibody company Kenta Biotech, Zurich. He is involved in scientific expert working groups and is a regular speaker at major scientific conferences. Since 2007, he has been the Chief Development Officer of GeNeuro.


Miguel Payró, Chief Financial Officer
Miguel has worked in corporate finance since 1985, first in various Swiss banks and then in industry since 1991, working in strong growth environments, initially with Unilabs SA, a European leader in clinical laboratory testing, for which he was in charge of the Swiss IPO and of numerous M&A transactions and international development. From 2003 to 2015 he was Chief Financial Officer of the Franck Muller luxury watch group in Switzerland, where he led, amongst other things, numerous M&A, tax and shareholder transactions, before joining GeNeuro in 2015 as CFO. Miguel graduated from the University in Geneva with a degree in business administration.


Robert Glanzman, Chief Medical Officer
Robert received his doctorate in medicine from Wake Forest University School of Medicine in the US. He completed an internship in internal medicine at New York Medical College, a residency in neurology at the University of Michigan, and a fellowship in diagnostic nuclear medicine at Duke University. Robert spent 7 years as an Associate Clinical Professor, where he had a busy clinical practice, taught residents and acted as principal investigator for clinical studies. Robert has been certified by the American Board of Psychiatry and Neurology since 1994.
Robert joined industry in 1999. He spent eight years at Pfizer, where he had been Senior Medical Director and Team Leader of the medical affairs team for ©Rebif; he then worked for Novartis starting in 2007, with medical responsibility for the successful Phase III development in the US of ©Gilenya and the commercial launch of ©Extavia. In 2009, he was recruited by Roche Group as Group Medical Director and was in charge from 2009 to 2012 of the ocrelizumab development team, leading this project from the end of Phase II through initiation of Phase III. In 2012, he joined Purdue Pharmaceuticals as Director of Clinical Research. In 2013, he was hired by Nektar Therapeutics as Vice President, Clinical Development. Robert has been in charge of the medical affairs of the Company since December 2015.